New fastGEN kits for the fast and efficient determination of the mutational status of oncogenes


BioVendor-Laboratorni medicina a.s.

New fastGEN kits for the fast and efficient determination of the mutational status of oncogenes

A personalized approach and knowledge of the mutational status of oncogenes is important for effective cancer treatment or prognosis. 

That is why we are expanding the fastGEN portfolio with other user-friendly kits for the analysis of TP53, PIK3CA, TERT, and CTNNB1 genes. The unique fastGEN technology is based on ultra-deep sequencing of short amplicons obtained by a single polymerase chain reaction with specially labelled hybrid primers. 

For simple analysis of fastGEN data, the GENOVESA software is a natural part of our kits, which also serves as a database for storing variants, with the possibility of sharing data between individual clinics. The advantage of the software is, for example, automated bioinformatic analysis of NGS data, advanced quality control of sequencing data and a report with clinical interpretation.

New pieces of the fastGEN puzzle
Using our unique fastGEN technology, we have created additional panels for the detection of clinically relevant mutations that play a role in various cancer diseases. 

Mutations in the TP53 gene (Tumor protein p53) are associated with many types of cancer, including hereditary ones. With the fastGEN TP53 Cancer kit, it is possible to detect mutations in exons 2-11 as well as in the two non-canonical exons between exons 9 and 10. 

The PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha) gene is the most frequently mutated gene in breast cancer and has been found to be important in other types of cancer as well. Exons 2, 3, 5, 7, 8, 10, 14 and 21 are covered in the fastGEN PIK3CA Cancer kit.  
Mutations in the TERT (Telomerase Reverse Transcriptase) gene are associated with an increased risk of various types of cancer, especially melanoma and myeloid leukemia. fastGEN TERT Cancer kit is focused on the promoter region, where somatic mutations occur much more often. Together with the fastGEN Brain Cancer kit which is aimed to detect mutations in IDH 1 and IDH 2 genes, it creates an ideal combination for determining the correct diagnosis or prognosis for the patient.

We enriched the fastGEN POLE kit with selected codons of exons 3, 7 and 8 of the CTNNB1 (Catenin Beta 1) gene, which is associated with colorectal cancer and ovarian cancer. This expanded kit will provide more important information for clinical evaluation.

Exhibitor Data Sheet